ArticleCureus2025
Dilemmas in the Management of Digital Ulcers in Systemic Sclerosis-Mixed Connective Tissue Disease: Lessons From a Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) is a rare autoimmune disorder marked by fibrosis and microvascular injury, commonly manifesting as digital ulcers and skin thickening. Lower limb ulcers are uncommon but can contribute to significant morbidity, need prolonged healing, and carry the risk of progression to necrosis or amputation, particularly in systemic sclerosis-mixed connective tissue disease (SSc-MCTD). We report a case of a 57-year-old woman with Raynaud's phenomenon, inflammatory small-joint arthritis, alopecia, photosensitive rash, and exertional dyspnea. Despite improvement in arthritis with disease-modifying antirheumatic therapy, a lower limb ulcer progressed while she was on vasoactive therapy (α-adrenergic blockade, phosphodiesterase-5 inhibition, endothelin-receptor antagonism) and immunomodulation, culminating in necrosis and pain that required amputation of the great toe and subsequently the forefoot. Laboratory evaluation revealed systemic inflammation and dyslipidemia, while vascular imaging demonstrated both microvascular and macrovascular compromise. Histopathology confirmed acute inflammatory changes without primary vasculitis. Rheumatology evaluation and serology established a diagnosis of SSc-MCTD, after which management was refocused on targeted vasodilation, immunomodulatory therapy, and multidisciplinary wound care. This case underscores the central role of vasculopathy in SSc-MCTD, highlights the limited efficacy of surgical intervention without optimized medical management, and emphasizes the importance of early involvement of Rheumatology and coordinated multidisciplinary care to prevent progression to irreversible ischemic injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.